ALK gene amplification is associated with poor prognosis in colorectal carcinoma
about
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma.Identification of ALK gene alterations in urothelial carcinoma.Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type statusAnaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication.Oncodomains: A protein domain-centric framework for analyzing rare variants in tumor samples.ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.ALK: a tyrosine kinase target for cancer therapy.Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers.The State of the Art in Colorectal Cancer Molecular Biomarker Testing.A new look at the ALK gene in cancer: copy number gain and amplification.Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer.Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.
P2860
Q26775347-CC176328-3AD8-474E-A9F4-77164A4AE7B8Q27852699-25BE5119-D5DC-43DB-9EF3-263E08DC5F99Q33945376-FC11397F-FA5D-4477-96D4-6C53FBD541E9Q33989002-5F8ACBC6-D6A9-4609-9951-9FE1E3FC4D93Q35136824-D2C1F306-07AF-476A-AB88-E00CC62A4CBEQ35137474-A08F8EA0-D898-427F-BCA1-98274EABB117Q35214370-93810EA7-0F1E-46BF-9B30-964E95853A5DQ36351953-423FB9BB-14E2-4A89-AEA1-6B10769D082CQ37209474-A9CF70A1-4B28-42C5-B4C7-300E3C399D2EQ37518624-910F6B4B-4DFE-4BCB-87ED-E7FACBB81C9EQ38563527-9F6FD64D-8E33-4876-949F-F068A97207D9Q38724312-DC78C490-CB56-4E18-A1DA-C102C430009FQ38760747-C8B33D57-AAC8-4ACD-952C-C728AB5592C2Q38829675-BE20467D-2430-4615-A220-2764A3A1A453Q41354652-0E95CFA4-A740-4D78-813F-104190ACFB5FQ47442252-A6395FA4-FBA8-4A35-B9DE-5E3139D9A3EC
P2860
ALK gene amplification is associated with poor prognosis in colorectal carcinoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ALK gene amplification is associated with poor prognosis in colorectal carcinoma
@en
ALK gene amplification is associated with poor prognosis in colorectal carcinoma.
@nl
type
label
ALK gene amplification is associated with poor prognosis in colorectal carcinoma
@en
ALK gene amplification is associated with poor prognosis in colorectal carcinoma.
@nl
prefLabel
ALK gene amplification is associated with poor prognosis in colorectal carcinoma
@en
ALK gene amplification is associated with poor prognosis in colorectal carcinoma.
@nl
P2093
P2860
P356
P1476
ALK gene amplification is associated with poor prognosis in colorectal carcinoma
@en
P2093
F Al-Dayel
K S Al-Kuraya
M Al-Assiri
S Prabhakaran
T Al-Halouly
P2860
P2888
P304
P356
10.1038/BJC.2013.641
P407
P577
2013-10-15T00:00:00Z